Biophan to Be Featured on WALLSTREETCAST on BRAVO Network Friday June 16, 2006 at 6:30 A.M. EDT.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH; FWB:BTN), a developer of next-generation medical technology, today announced that WALLSTREETCAST, a half-hour financial program that covers the Small-cap stock market arena, will feature Biophan Technologies, Inc. in its latest edition which airs on the BRAVO(TM) Network at 6:30 a.m. EDT, on Friday, June 16, 2006, and for several weeks thereafter.

BRAVO(TM) airs in an estimated 78 million cable television households. This program will also air starting next week on The Healthy Living Channel on Thursday evening at 8:00 p.m., EDT, and The Men's Channel on Sunday at 12:30 p.m., EDT. WALLSTREETCAST, hosted by Steve Crowley, is also "Close-Captioned for the Hearing Impaired". This Biophan segment featuring CEO Michael Weiner was produced in part at the Company's headquarters in Rochester, New York.

WALLSTREETCAST airs in the same time period on BRAVO(TM) each week which is part of its regular paid programming on Friday mornings at 6:30 a.m. to 7:00 a.m. EDT.

About Biophan

Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI), problems which the Company has solved and begun to license to leading device manufacturers. The Company's mission has expanded to provide other technologies which will improve the delivery of healthcare. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYO-VAD(TM), a novel, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of over 200 U.S. and foreign patents, licenses, or applications. This total includes 56 issued U.S. patents, and over 100 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.

In connection with the Annual Meeting, Biophan will prepare a proxy statement to be distributed to its shareholders and filed with the SEC. Before making any voting decision, Biophan's shareholders are urged to read the proxy statement carefully in its entirety when it becomes available because it will contain important information about the Annual Meeting and the actions to be taken. The proxy statement and other relevant documents filed with the SEC will be available free of charge at the SEC's website, www.sec.gov and investors will also be able to obtain copies of the proxy statement and other relevant documents free of charge by directing their requests to Investor Relations, Biophan Technologies, Inc., 150 Lucius Gordon Drive, W. Henrietta, NY 14586.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.